INTRODUCTION

For thousands of years, many metal-based compounds have had application as therapeutic agents. Application of zinc and silver in healing of wounds and infection prevention dates back to ancient times [1]. Nowadays, cisplatin and auranofin, two important drugs based on platinum and gold metals, are widely used for the treatment of cancer and rheumatoid arthritis, respectively [2, 3]. Although platinum and ruthenium are non-biogenic elements, many of their complexes have shown potential application in cancer therapy [4, 5].

Due to their diversity, various metal complexes have shown therapeutic effect in treatment of many diseases [2–8]. Currently, complexes of Cu(II), Zn(II), Ni(II) and Co(II) have found application as antimicrobial and antiviral agents [6, 7]. Some polyoxometalate complexes of early transition metals (W, V, Mo) have also shown promising medical application due to their antimicrobial, antiacetylcholinesterase and anticancer effects [8, 9].

Immediately after cardiovascular diseases, cancer is the leading cause of death in humans worldwide [4]. In recent years, the focus of interest in medicinal chemistry has been application of metal complexes in treatment of malignant diseases [2–5]. Cancer therapy includes the surgical removal of tumor, radiation therapy and chemotherapy. Currently, diverse platinum complexes have found application in cancer therapy as chemotherapeutic agents, while many new synthesized complexes of gallium, gold, titanium, and ruthenium are intensively studied. Some ruthenium complexes attract special attention due to their promising results in clinical trials [5]. The main goal of this paper is to consider current knowledge of the platinum and ruthenium complexes related to anticancer therapy. Some of these complexes are clinically approved, while some of them including the ruthenium complexes have entered or may enter clinical trials soon.

PLATINUM ANTICANCER COMPLEXES

Despite thousands of novel platinum complexes, only three of them are presently in clinical use in anticancer therapy: cisplatin, carboplatin, and oxaliplatin [2, 4, 5]. These drugs are administered intravenously, and beside their good anticancer activity, they show some side-effects such as toxicity and acquired resistance which significantly limits their clinical application [2, 4, 5].

For nearly 40 years, cisplatin (cis-diamminodichloroplatinum(II), cis-\([\text{PtCl}_2(\text{NH}_3)_2]\) (Figure 1) has been the most widely used chemotherapeutics in oncology, and it is being administered to ca 50% of all cancer patients [4,
Cisplatin, whose trade name is Platinol, is a leading anticancer drug used in therapy of testicular, ovarian, lung, head, neck, and bladder carcinomas. It is square-planar complex whose activity is reflected by hydrolysis of chloride ligands in the cells. The complex binds to DNA across nitrogen N7 atoms of nucleobases (guanine and adenine) forming stable intrastrand links (1,2-GpG and 1,2-ApG) (Figure 1) [2, 4]. The DNA cross-linking leads to distort conformations, blocks replication, prevents transcription and triggers apoptosis. Unfortunately, cisplatin shows some disadvantages such as cumulative toxicity including nephrotoxicity, neurotoxicity, ototoxicity, nausea, hair loss, and treatment-induced resistance [2, 4, 5]. Resistance to cisplatin results from complex mechanisms at molecular and cellular levels including reduction in cellular accumulation, increased inactivation by SH-proteins, altered expression of regulatory genes, increased levels of DNA damage repair and increased adduct tolerance [11]. These drawbacks encourage the development of novel cisplatin analogues with improved properties.

Carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II), whose trade name is Paraplatin, is the second generation of Pt(II) drugs which, compared to cisplatin, has a bidentate dicarboxylate ligand instead of two labile chloride ligands (Figure 1). Higher stability of this complex causes consequently lower toxicity leading to a long-lasting effect. To be more precise, carboplatin needs more time to reach the target biomolecules (retention half-life of 30 hours) compared to cisplatin (1.5–6 hours), forming the same type of DNA adducts [2, 4, 5, 12]. Carboplatin has showed lower toxicity than cisplatin, an insignificant nephrotoxicity in particular, being effective against some types of cancer that are not sensitive to cisplatin [2, 4, 5, 12].

Oxaliplatin [oxalato(2-)-O,O’][1R,2R-cyclohexanediamine-N,N’] platinum(II), whose trade name is Eloxatin, was the first drug to successfully overcome resistance to cisplatin due to the replacement of two amine ligands in cisplatin with stable bidentate ligand, (1R,2R)-cyclohexane-1,2-diamine (R,R-DACH) (Figure 1) [2, 4, 5, 13]. Oxaliplatin is a third generation of Pt(II) compounds whose high cytotoxicity and noncross-resistance can be attributed to voluminous, hydrophobic DACH ligand that interacts significantly with major groove of DNA and prevents repair pathway. High cytotoxicity of oxaliplatin to cancer cells is caused by formation of more damaging Pt-DNA adducts, mainly intrastrand 1,2-GpG linked [13].

There are four platinum complexes that currently have importance in advance clinical trials due to either their oral bioavailability (satraplatin and picoplatin) [14] or to improved polymer and liposomal drug delivery systems with lower toxicity (prolindac and lipoplatin) [15–18].

Satraplatin (bis-(acetato-O)amminedichloro(cyclohexylamine)platinum(IV), whose trade name is Orplatna, is a Pt(IV) octahedral complex with two axial monodentate acetate ligands, which enable its bioavailability as the first platinum oral administrated therapeutic agent (Figure 1) [4, 5, 14]. Lower toxicity and lower side effects of satraplatin come from less activity of Pt(IV) compared to Pt(II) complexes (cisplatin, carboplatin, oxaliplatin), its rapid absorption through gastrointestinal mucosa and reduction to at least six different Pt(II) metabolites, out of which cis-amminedichloro-(cyclohexylamine)platinum(II) is the most abundant [14]. This metabolite is bound to DNA by 1,2-intrastrand cross-links inducing apoptosis. All metabolites of satraplatin mainly bind to plasma proteins with negligible percentage of their decomposition to free platinum. Satraplatin overcame Phase III clinical trials showing significant anticancer activity to several platinum-resistant human cancer cell lines, including lung, ovarian, and prostate cancer [14].

Picoplatin (cis-(amminedichloro-2-methylpyridine)platinum(II) is an analog of cisplatin, where an ammine ligand is substituted with bulkier 2-methylpyridine re-

Figure 1. Development pathway of platinum drugs in cancer therapy

DOI: https://doi.org/10.2298/SARH180706075A

Srp Arh Celok Lek. 2019 Jan-Feb;147(1-2):105-109
sponsible for steric shielding around platinum(II) center (Figure 1). This ligand prevents nucleophilic attacks of SH-proteins such as glutathione, and overcomes cisplatin resistance. To be more precise, picoplatin is designed in such a way to lead slower substitution kinetics due to glutathione competition through dissociative thiol substitution, instead of an associative mechanism like in cisplatin [5, 14]. Lower toxicity of picoplatin compared to cisplatin has been confirmed, particularly regarding nephro- and neurotoxicity, showing anticancer activity in the cisplatin resistance cancer lines such as lung, colorectal, and prostate cancers. Picoplatin treatments in combination with 5-fluorouracil (FU) and leucovorin for colorectal cancer, as well as in combination with docetaxel for prostate cancer, have reached phases I and II of clinical trials [5].

In recent years, in order to improve delivery of Pt(II) drugs, reduce toxicity and get better drug tolerance profile, new liposomal and polymer based drug delivery systems have been developed [15–18]. Pt(II) drugs encapsulated in a liposome or in specially designed polymer have found various advantages over Pt(II) drugs: they have better solubility, biocompatibility, better membrane permeability, drug stability within delivery systems, and higher retention time.

Prolindac is a drug-delivery system of oxaliplatin, encapsulated in hydrophobic biocompatible polymer hydroxypropylmethaacrylamide (HPMA), which, compared to oxaliplatin, have shown higher activity and lower toxicity (neurotoxicity) in various human cancers in phase II of clinical trials (Figure 1) [4, 5, 18]. Clearly enough, HPMA polymer has the role of delivery system of oxaliplatin to the target cancer cells where it undergoes decomposition due to the low pH value within the cancer cells [4]. Prolindac has shown significant anticancer activity for treatments of breast, ovarian, lung, and prostate cancers, especially for metastatic melanoma and ovarian cancer.

Liposomal formulations of cisplatin (lipoplatin, TRX-20), oxaliplatin (lipoxal), and an oxaliplatin analogue (aroplatin) have been created recently (Figure 1) [16, 17]. Lipoplatin has overcome phases I, II, and III of clinical trials showing remarkable anticancer properties due to small sized particles (90 to 130 nm), causing easier cross through cell membranes and consequently fewer side effects, particularly negligible nephrotoxicity, ototoxicity and neurotoxicity. Lipoplatin has high anticancer activity against metastatic tumors, particularly prostate, colon, gastric, and lung cancers [16]. Cisplatin encapsulated in cationic lipid polyethylene glycol-coated liposomes (TRX-20) has shown increased delivery time to target molecules, high bioavailability, and anticancer activity in treatments of some metastatic cancers, especially refractory prostate, colon, gastric and lung cancers [5].

In recent years, polinuclear bridged platinum complexes (Figure 1) have also attracted particular attention, since they have two or three platinum centers which are able to bind at several sites along the DNA helix, causing more severe DNA damage and being more effective against cancer cells as compared to cisplatin analogues [4, 15].

**RUTHENIUM ANTICANCER COMPLEXES**

Non-platinum complexes based on ruthenium, gold, palladium or titanium, have been investigated in the quest for compounds with lower toxicity and higher selectivity compared to cisplatin. Ruthenium compounds have specific physicochemical properties that make them promising as anticancer agents: (a) activation by reduction (from Ru(III) to Ru(II)), (b) different coordination geometry compared to platinum, and (c) favorable ligand-exchange kinetics [19].

In the last two decades, many papers have documented the great anticancer potential of ruthenium complexes, both in vivo and in vitro. Three of the most investigated ruthenium drugs are NAMI-A ([H₂Im][trans-RuCl₄(DMSO)(Im)]) (Figure 2a), KP1019 (trans-[tetrachlorobis(1H-indazole)ruthenate(III)]) (Figure 2b), and sodium derivative of KP1019, KP1339 (Figure 2c). All three compounds have entered Phases I and II of clinical trials.

NAMI-A has significant efficacy in inhibiting tumor metastasis [20], while this compound, in vitro, has low potency in terms of cytotoxicity towards cancer cells. The mode of action of NAMI-A is not clear and many papers documented potency of this complex for binding to DNA and RNA [20, 21]. KP1019 synthesized by the Keppler group entered clinical trials [22], but the main problem in the
clinical investigations for KP1019 is its low solubility under physiological conditions. With better solubility, sodium salt KP1339, is currently undergoing clinical trials [23].

Arene ruthenium(II) complexes, general formula [(η^6-arene)Ru(X)(Y)(Z)], where X and Y can be two monodentate or one bidentate ligand (Figure 3a and 3b), were first investigated in the field of anticancer compounds by Sadler and Dyson [24]. The presence of the chelating ligand provides the additional stability of the whole structure. Monodentate ligand Z is a good leaving group (in the most cases halogen). These complexes showed piano stool geometry, where arene is benzene (ben) or methylisopropyl benzene (cym) or biphenyl (bip) or dihydroanthracene (dha) which provide hydrophobicity of molecule and ensure the entry of the complexes in the cell [24]. It was shown for some complexes of this type that the cytotoxicity increases with the arene moiety size because of the greater ability of the arene to intercalate into DNA. Also, aromatic part stabilizes ruthenium center in oxidation state + 2. For the complexes general formula, [(η^6-arene)Ru(en)Cl]+, (en = ethylenediamine) it has been shown that cytotoxicity increases in the series arene: benzene < p-cymene < biphenyl < dihydroanthracene < tetrahydroanthracene [25].

CONCLUSION

Cisplatin has so far been the most used chemotherapeutic agent, regardless of its disadvantages such as cumulative toxicity and development of cancer cell resistance. With aim to overcome these side effects, many novel platinum complexes have been synthesized and studied. Regrettably enough, only about 20 out of thousands of new platinum compounds have reached clinical trials. After development of second (carboplatin) and third (oxaliplatin) generation of platinum(II) drugs, by replacement of chloride and ammine ligands in cisplatin respectively, further research has led to polymer or liposome formulations of platinum(II) drugs and new dinuclear and oligonuclear platinum complexes. In recent years, ruthenium complexes have had a huge potential for application in cancer therapies, being the only non-platinum compounds that have entered clinical trials.

ACKNOWLEDGMENT

This work was financially supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia (projects 172023, III 46010, and 172035).

REFERENCES

1. Orvig C, Abrams MJ. Medicinal inorganic chemistry: introduction. Chem Rev. 1999; 99(9):2201–3.
2. Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr Opin Chem Biol. 2003; 7(4):481–9.
3. Suwalsky M, Gonzalez R, Villena F, Bolognin S. Structural effects of the Au(II) drug Auranofin on cell membranes and molecular models. J Chil Chem Soc. 2013; 584(4):2001–4.
4. Marques MM, Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor. ISRN Spectroscopy. 2013; 2013:1–29.
5. Ndagi U, Mhlongo N, Soliman ME. Metal complexes in cancer therapy – an update from drug design perspective. Drug Des Deliv Ther. 2017; 11:599–616.
6. Sovilj SP, Avramović N, Katsaros N. Synthesis and properties of mixed copper(II) complexes with heterocyclic dithiocarbamates and a cyclic octadentate tertiary amine. Transit Metal Chem. 2004; 29(7):377–42.
7. Rizzotto M. Metal Complexes as Antimicrobial Agents. In: Bobbbarala V, editor. A Search for Antibacterial Agents. Intech Open; 2012. p. 73–88.
8. Čolović M, Bajuk-Bogdanović DV, Avramović N, Holcátner-Antunović I, Bošnjaković-Pavlović NS, Vasić V, et al. Inhibition of rat synaptic membrane Na(+)-K(+)-ATPase and ecto-nucleoside triphosphate diphosphohydrolases by 12-tungstosilicic and 12-tungostophosphoric acid. Bioorg Med Chem. 2011; 19(2):7063–9.
9. Hasenkopf B. Polyyoxometalates: introduction to a class of inorganic compounds and their biomedical applications. Front Biosci. 2005; 10:2725–87.
10. Rosenberg B, Vancamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969; 222(5191):385–6.
11. Kartalou M, Eissmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001; 478(1-2):23–43.
12. Fricker SP. Metal based drugs: from serendipity to design. Dalton Trans. 2007; 43:4903–17.
13. Raymond E, Fairev S, Chaney S, Woynarowski J, Cvtovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002; 1(3):227–35.
14. Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues: satraplatin and picoplatin. Expert Opin Investig Drugs. 2007; 16(7):1009–21.
15. Prisecaru A, Molphy Z, Kipping RG, Peterson EJ, Qu Y, Kellett A, et al. The phosphate clamp: sequence selective nucleic acid binding profiles and conformational induction of endonuclease inhibition by cationic Triplatin complexes. Nucleic Acids Res. 2014; 42(22):13474–87.
16. Lamichhane N, Udayakumar TS, D’Souza WD, Simone CB, Raghavan SR, Folf J, et al. Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery. Molecules. 2018; 23(2):288.
17. Liu D, He C, Wang AZ, Lin W. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomed. 2013; 8:3309–19.
18. Johnstone TC, Suntharalingam K, Lippard SJ. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev. 2016; 116(5):3436–86.
19. Antonarakis ES, Emadi A. Ruthenium-based chemotherapeutics: are they ready for prime time? Cancer Chemother Pharmacol. 2010; 66(1):1–5.
20. Sava G, Gagliardi R, Cocchiotti M, Clerici K, Capozzi I, Marrella M, et al. Comparison of the effects of the antineoplastic compound ImHtrans-RuCl4(DMOS0Im) (NAMI-A) on the arthritic rat and on MCA mammary carcinoma in mice. Pathol Oncol Res. 1998; 4(1):30–6.
21. Bacac M, Vadori M, Sava G, Pacor S. Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells. Cancer Immunol Immunother. 2004; 53(12):1101–10.
22. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. From bench to bedside-preclinical and early clinical development of the anticancer agent indazolom trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP1019 or FFC14A. J Inorg Biochem. 2006; 100(5-6):891–904.
23. Bytyzek AK, Koellensperger G, Keppler BK, Hartinger CG. Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP1019 or FFC14A. J Inorg Biochem. 2016; 160:250–5.
24. Dougan SJ, Sadler PJ. The Design of Organometallic Ruthenium Arene Anticancer Agents. Chimia. 2007; 61(11):704–15.
25. Savic A, Dulovic M, Poljarovic J, Misirlic-Dencic S, Jovanovic M, Bogdanovic A, et al. Synthesis, and in vitro anticancer activity of ruthenium-cymene complexes with cyclohexyl derivatives of ethylenediamine-N,N'-type ligands. Chem Med Chem. 2011; 6(10):1884–91.
Комплекси платине и рутенијума – обећавајући молекули у терапији карцинома

Наташа Аврамовић1,2, Никола Игњатовић2, Александар Савић3

1Универзитет у Београду, Институт за хемију у медицини, Медицински факултет, Београд, Србија;
2Универзитет у Београду, Медицински факултет, Београд, Србија;
3Универзитет у Београду, Хемијски факултет, Београд, Србија

САЖЕТАК
Карциноми су један од водећих узрока смртности светске популације. Процењује се да ће у наредне две деценије око 20 милиона људи у свету имати постављену дијагнозу карцинома. Главни задатак медицинске хемије јесте добијање нових хемиотерапеутских агенаса са бољим антиканцерским својствима.

Cisplatin се примењује у онкологији од 1978. године, као први хемиотерапеутски агенс који специфично долази у интеракцију са молекулима ДНК, доводи до ДНК оштећења и узрокује ћелијску смрт. Од када је цисплатин нашао примену у терапији карцинома, расте интересовање за новим једињењима који садрже метале, а посебно за комплексима платине и рутенијума, са већом антиканцерском активношћу и мање нежељених дејстава у поређењу са цисплатином. Carboplatin и oxaliplatin су се показали ефикасним у третману неких типова карцинома резистентних на цисплатин. Са циљем превазилажења резистентности на ове Pt(II)-лекове, најпре су комплекси платине (satraplatin и picoplatin) нашли примену као први орални лекови, као и комбиноване терапије појединих Pt(II)-лекова (cisplatin, picoplatin) са специфично резистентним модулаторима. Последњих година дизајниране су нове полимерне и липозомалне формулације лекова платине (prolindac, lipoplatin, lipoxal, aroplatin) због боље циљне испоруке лека до туморских ћелија и њихове смањене токсичности. Комплекси рутенијума имају велику могућност примене у терапији карцинома. Ова једињења показују добру антиканцерску активност, како in vitro, тако и in vivo, а два комплекса рутенијума (KP1019 и NAMI-A) показала су добре резултате у клиничким испитивањима.

Кључне речи: терапија карцинома; платина; рутенијум; метални комплекси; антиканцерска активност